GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » Cyclically Adjusted Book per Share

Nektar Therapeutics (Nektar Therapeutics) Cyclically Adjusted Book per Share : $3.75 (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Nektar Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $0.684. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.75 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Nektar Therapeutics's average Cyclically Adjusted Book Growth Rate was 7.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 10.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 20.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Nektar Therapeutics was 49.10% per year. The lowest was -26.50% per year. And the median was -0.85% per year.

As of today (2024-05-01), Nektar Therapeutics's current stock price is $1.46. Nektar Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $3.75. Nektar Therapeutics's Cyclically Adjusted PB Ratio of today is 0.39.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nektar Therapeutics was 130.53. The lowest was 0.12. And the median was 7.26.


Nektar Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Nektar Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Cyclically Adjusted Book per Share Chart

Nektar Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.17 2.75 3.15 3.48 3.75

Nektar Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.48 3.57 3.65 3.72 3.75

Competitive Comparison of Nektar Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PB Ratio falls into.



Nektar Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nektar Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.684/129.4194*129.4194
=0.684

Current CPI (Dec. 2023) = 129.4194.

Nektar Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 -0.077 99.695 -0.100
201406 -0.278 100.560 -0.358
201409 0.368 100.428 0.474
201412 0.277 99.070 0.362
201503 0.588 99.621 0.764
201506 0.266 100.684 0.342
201509 0.293 100.392 0.378
201512 0.048 99.792 0.062
201603 -0.002 100.470 -0.003
201606 -0.287 101.688 -0.365
201609 -0.492 101.861 -0.625
201612 0.575 101.863 0.731
201703 0.289 102.862 0.364
201706 0.022 103.349 0.028
201709 0.536 104.136 0.666
201712 0.551 104.011 0.686
201803 0.359 105.290 0.441
201806 10.790 106.317 13.135
201809 10.344 106.507 12.569
201812 9.898 105.998 12.085
201903 9.376 107.251 11.314
201906 8.900 108.070 10.658
201909 8.469 108.329 10.118
201912 7.962 108.420 9.504
202003 7.289 108.902 8.662
202006 7.026 108.767 8.360
202009 6.527 109.815 7.692
202012 5.982 109.897 7.045
202103 5.456 111.754 6.318
202106 4.924 114.631 5.559
202109 4.343 115.734 4.857
202112 3.664 117.630 4.031
202203 3.263 121.301 3.481
202206 2.448 125.017 2.534
202209 2.193 125.227 2.266
202212 1.944 125.222 2.009
202303 1.273 127.348 1.294
202306 1.036 128.729 1.042
202309 0.835 129.860 0.832
202312 0.684 129.419 0.684

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Nektar Therapeutics  (NAS:NKTR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Nektar Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.46/3.75
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nektar Therapeutics was 130.53. The lowest was 0.12. And the median was 7.26.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Nektar Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics (Nektar Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Executives
Howard W Robin director, officer: President & CEO
Jonathan Zalevsky officer: Chief R&D Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Mark Andrew Wilson officer: SVP & General Counsel 1613 RAY DRIVE, BURLINGAME CA 94010
Myriam Curet director 1020 KIFER ROAD, SUNNYVALE CA 94086
Jeffrey Robert Ajer director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Sandra A. Gardiner officer: Chief Financial Officer CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jillian B. Thomsen officer: VP & Chief Accounting Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Robert Chess director, officer: Executive Chairman
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Gil M Labrucherie officer: SVP, COO & CFO 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
John Northcott officer: SVP & Chief Commercial Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Diana Brainard director C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
R Scott Greer director 6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253
Lutz Lingnau director 15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945
Stephen K Doberstein officer: Chief Scientific Officer 129 ELSIE STREET, SAN FRANCISCO CA 94110

Nektar Therapeutics (Nektar Therapeutics) Headlines

From GuruFocus

Should Investors Worry About Nektar Therapeutics's Insider Sells?

By GuruFocus Research GuruFocus Editor 05-19-2023

This Insider Just Sold Shares of Nektar Therapeutics

By GuruFocus Research GuruFocus Editor 02-18-2023